{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T17:04:42Z","timestamp":1772298282809,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001869","name":"Academia Sinica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001869","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science and Technology"},{"DOI":"10.13039\/501100008761","name":"Taiwan Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008761","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ejmech.2016.07.025","type":"journal-article","created":{"date-parts":[[2016,7,17]],"date-time":"2016-07-17T00:43:39Z","timestamp":1468716219000},"page":"14-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency"],"prefix":"10.1016","volume":"123","author":[{"given":"Wei-Chieh","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Hon","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Jhih","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Ming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Yi","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Hsin","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2016.07.025_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1875397301004010050","article-title":"Fabry disease \u2013 current treatment and new drug development","volume":"4","author":"Motabar","year":"2010","journal-title":"Curr. Chem. Genomics"},{"key":"10.1016\/j.ejmech.2016.07.025_bib2","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1021\/cb500143h","article-title":"Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human \u03b1-galactosidase A: pharmacological chaperoning efficacy on Fabry disease mutants","volume":"9","author":"Yu","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2016.07.025_bib3","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.cca.2010.03.009","article-title":"Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry","volume":"411","author":"Dajnoki","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2016.07.025_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2016.07.025_bib5","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2016.07.025_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A\u00a0retrospective analysis of the potential impact of IgG antibodies to agalsidase \u03b2 on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol. Gen. Metab."},{"key":"10.1016\/j.ejmech.2016.07.025_bib7","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood\u2013brain barrier","volume":"14","author":"Begley","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2016.07.025_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A\u00a0phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2016.07.025_bib9","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2016.07.025_bib10","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbrc.2008.02.125","article-title":"Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase","volume":"369","author":"Shen","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2016.07.025_bib11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2016.07.025_bib12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human \u03b1-galactosidase A tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2016.07.025_bib13","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1021\/jm301557k","article-title":"Pharmacological chaperones as therapeutics for lysosomal storage diseases","volume":"56","author":"Boyd","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.07.025_bib14","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1039\/C6CC01564F","article-title":"Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry disease","volume":"52","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2016","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2016.07.025_bib15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2016.07.025_bib16","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In\u00a0vitro inhibition and intracellular enhancement of lysosomal \u03b1-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2016.07.025_bib17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases \u03b1-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ejmech.2016.07.025_bib18","doi-asserted-by":"crossref","first-page":"11696","DOI":"10.1002\/anie.201505147","volume":"54","author":"Mena-Barrag\u00e1n","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2016.07.025_bib19","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1016\/j.bmc.2010.04.048","article-title":"2,5-Dideoxy-2,5-imino-D-altritol as a new class of pharmacological chaperone for Fabry disease","volume":"18","author":"Kato","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.07.025_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/1875397301004010067","article-title":"High throughput screening for inhibitors of \u03b1-galactosidase","volume":"4","author":"Motabar","year":"2010","journal-title":"Curr. Chem. Genomics"},{"key":"10.1016\/j.ejmech.2016.07.025_bib21","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1016\/j.bmc.2013.06.054","article-title":"Rapid modifications of N-substitution in iminosugars: development of new \u03b2-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease","volume":"21","author":"Cheng","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.07.025_bib22","doi-asserted-by":"crossref","first-page":"7777","DOI":"10.1021\/jo301243s","article-title":"Glycosidase inhibition by all 10 stereoisomeric 2,5-Dideoxy-2,5-iminohexitols prepared from the enantiomers of glucuronolactone","volume":"77","author":"Ayers","year":"2012","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2016.07.025_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tet.2008.10.096","article-title":"A\u00a0convenient approach toward the synthesis of enantiopure isomers of DMDP and ADMDP","volume":"65","author":"Tsou","year":"2009","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2016.07.025_bib24","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1002\/asia.201300680","article-title":"From natural product-inspired pyrrolidine scaffolds to the development of new human Golgi \u03b1-mannosidase II inhibitors","volume":"8","author":"Cheng","year":"2013","journal-title":"Chem. Asian J."},{"key":"10.1016\/j.ejmech.2016.07.025_bib25","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S \u03b2-glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2016.07.025_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ymgme.2012.06.007","article-title":"Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy","volume":"107","author":"Rigat","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ejmech.2016.07.025_bib27","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/nprot.2007.321","article-title":"The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability","volume":"2","author":"Niesen","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2016.07.025_bib28","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/glycob\/cws112","article-title":"Comparative structural analysis of the glycosylation of salivary and buccal cell proteins: innate protection against infection by Candida albicans","volume":"22","author":"Everest-Dass","year":"2012","journal-title":"Glycobiology"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416305736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416305736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T01:28:32Z","timestamp":1589678912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523416305736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":28,"alternative-id":["S0223523416305736"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.07.025","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}